Francesco Rotella

Dr. Francesco Rotella

University of Florence, Italy, USA
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2013 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
FRFrancesco Rotella
Francesco Rotella
EMEdoardo Mannucci
Edoardo Mannucci
From The Journal of Clinical Psychiatry:

1 February 2013 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
FRFrancesco Rotella
Francesco Rotella
EME. Mannucci
E. Mannucci

1 July 2005 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
EME. Mannucci
E. Mannucci
FRFrancesco Rotella
Francesco Rotella
VRvaldo ricca
valdo ricca
SMS. Moretti
S. Moretti
GPG. F. Placidi
G. F. Placidi
CRC. M. Rotella
C. M. Rotella

1 January 2011 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MCM. Catena-Dell'OSso
M. Catena-Dell'OSso
CBC. Bellantuono
C. Bellantuono
GCG. Consoli
G. Consoli
SBS. Baroni
S. Baroni
FRFrancesco Rotella
Francesco Rotella
Donatella MarazzitiDonatella Marazziti
Donatella Marazziti
The latest advancement in neurobiological research provided an increasing evidence that inflammatory and neurodegenerative pathways play a relevant role in depression. Preclinical and clinical studies on depression highlighted an increased production of inflammatory markers, such as interleukin (IL)-1, IL-6, tumor necrosis factor-α and interferon- αand γ. On the other hand, acute and chronic administration of cytokines or cytokine inducers were found to trigger depressive symptoms. According to the cytokine hypothesis, depression would be due to a stress-related increased production of pro-inflammatory cytokines that, in turn, would lead to increased oxidative and nitrosative brain damage and to indoleamine 2,3 dioxygenase (IDO) induction, with production of tryptophan (TRP) catabolites along the IDO pathway (TRYCATs) and consequent reduced availability of TRP and serotonin (5-HT). Cytokines would also play a role in the onset of the glucocorticoid resistance, underlying the overdrive of the hypothalamic-pituitary-adrenal axis. Therefore, the activation of the inflammatory and neurodegenerative pathways would lead to the brain damage observed in depression through both reduced neurogenesis and increased neurodegeneration. Besides the 5-HT system, other targets, possibly within the I&ND pathways, should be considered for the future treatment of depression: cytokines and their receptors, intracellular inflammatory mediators, IDO, TRYCATs, glucocorticoid receptors, neurotrophic factors may all represent possible therapeutic targets for novel antidepressants. In addition, it should be also clarified the role of the existing antiinflammatory drugs in the treatment of depression, and those compounds with the anti-inflammatory and anti-oxidative properties should be examined either as monotherapy or adjunctive therapy. In conclusion, the molecular inflammatory and neurodegenerative pathways might provide new targets for antidepressant development and might be crucial to establish a rational treatment of depression aimed, hopefully, to its causal factors.

1 April 2012 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
VRvaldo ricca
valdo ricca
GCGiovanni Castellini
Giovanni Castellini
GFGiulia Fioravanti
Giulia Fioravanti
CSCarolina Lo Sauro
Carolina Lo Sauro
FRFrancesco Rotella
Francesco Rotella
CFCarlo Faravelli
Carlo Faravelli

1 April 2013 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MCMario Catena-Dell’osso
Mario Catena-Dell’osso
FRFrancesco Rotella
Francesco Rotella
ADAdriana Dell’osso
Adriana Dell’osso
AFAndrea Fagiolini
Andrea Fagiolini
Donatella MarazzitiDonatella Marazziti
Donatella Marazziti
The understanding of the neurobiological processes leading to major depressive disorder (MDD) is an active field of research in the scientific community. For years, the alteration of monoamine neurotransmission, in particular serotonin (5-HT), has been considered the most significant pathophysiological mechanism of the disorder. However, biological data supporting the postulated MDD-related monoamine alterations have been inconclusive, and the use of monoaminergic antidepressants has not yielded the expected results. In the last few years, it has been demonstrated that inflammatory pathways have a significant role in the pathophysiology of MDD. According to the cytokine hypothesis, the disorder would be due to a stress-related increased production of cytokines, including interleukins, tumor necrosis factor-α and interferon- α and γ. These, in turns, would cause the activation of the indoleamine 2,3 dioxygenase (IDO), with subsequent production of tryptophan (TRP) catabolites along the IDO pathway (TRYCATs) and decreased availability of TRP and 5-HT. Besides monoamines, other molecular mechanisms, as those within the inflammatory pathways, should be taken into account in the attempt to clarify the pathophysiology of MDD and to improve its treatment.